4,4′-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): A topical treatment for cutaneous metastases from malignant cancers

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 6, 2006, Pages 719-726

  Eilender, David ^a   LoRusso, Patricia ^a   Thomas, Leonard ^c   McCormick, Catherine ^c   Rodgers, Andrew H ^b   Hooper, Catherine L ^b   Tornyos, Karl ^d   Krementz, Edward T ^b   Parker, Steven ^e   Morgan, Lee Roy ^b  

^a HARPER UNIVERSITY HOSPITAL   (United States)

^b DEKK TEC Incorporated   (United States)

^c MDs Inc ^*  (United States)

^d MDS Inc   (Canada)

^e Early Detection Clinic   (United States)

Author keywords

4,4 Dihydroxybenzophenone 2,4 dinitrophenylhydrazone; Breast cancer; Cutaneous metastases; Melanoma; T cell lymphoma

Indexed keywords

4,4' DIHYDROXYBENZOPHENONE 2,4 DINITROPHENYLHYDRAZONE; ANTINEOPLASTIC AGENT; MEGESTROL ACETATE; PHENYLHYDRAZONE DERIVATIVE; TAMOXIFEN; TOPICAL AGENT; UNCLASSIFIED DRUG; 4,4'-DIHYDROXYBENZOPHENONE-2,4-DINITROPHENYLHYDRAZONE; HYDRAZONE DERIVATIVE; PHENOL DERIVATIVE;

ADULT; AGED; ANEMIA; ANGIOSARCOMA; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ERUPTION; FEMALE; HUMAN; KAPOSI SARCOMA; MALE; MOUTH CARCINOMA; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PRURITUS; SKIN METASTASIS; SKIN TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME; METABOLISM; METASTASIS; MIDDLE AGED; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; MULTICENTER STUDIES; PHENOLS; SKIN NEOPLASMS;

EID: 33645743526     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0124-2     Document Type: Article

References (18)

1. Cantu' de Leon D, Alanis-Lopez P, Rodriguez-Trejo A et al (2003) Chestwall resection in breast cancer recurrence. In: 14th international congress on anti-cancer treat, Paris, pp 156-157
2. Leonard R, Hardy J, Van Tienhoven G, et al (2001) Randomized double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol 19:4150-4159
3. Maxfield WS (1967) Panel discussion - theory of recurrent disease. In: Segaloff A, Meyer KK, Debakay S (eds) Current concepts breast cancer, The Williams and Wilkins Co, Baltimore, pp 364-367
4. Barnhill RL, Mihm MC Jr (1992) Histopathology of malignant melanoma and its precursor lesions. In: Blach CM, Houghton AN, Milton GW, Sober AJ (eds) Cutaneous melanoma. JB Lippincott Co. Phil, PA, pp 234-263
5. Sezary A, Bouvrain Y (1938): Erythrodermine avec presence de cellules monstrueses dans le derme et dans le sang circulant. Bull Soc Fr Dermatol Symp 45:254-265
6. Safi B (1987) Pathophysiology and epidemiology of epidemic Kaposi's sarcoma. Semin Oncol 14 (suppl):7-23
7. Morgan LR, Judge KW, Gillen LE, Fan D, Leclercq G (1988) Substituted benzo-phenone phenylhydrazones for the treatment of hormone dependent tumors. Proc Am Assoc Cancer Res 25:243
8. Morgan LR, Rodgers AH, Hooper CL et al (2001) Comparative dermal pharmacology and toxicology of 4,4′-dihydroxybenzophenone-2,4- dinitrophenylhydrazone (A-007) in rodents and primates. In Vivo 15:479-484
9. Morgan LR, Jursic B, Morgan LR, et al (2002) Anticancer activity for 4,4′-dihydroxybenzophenone-2,4-dinitrophenylhydrazone analogs and their ability to interact with lymphoendothelial cell surface markers. Bioorg Med Chem Lett 12:3407-3411
10. Morgan LR, Rodgers A, Fan D, et al (1997) Comparative preclinical toxicology and pharmacology of 4,4′-dihydroxybenzophenone-2,4- dinitrophenylhydrazone (A-007) in vivo in rodents and primates. In Vivo 11:29-38
11. Morgan LR, Thangaraj K, LeBlanc B, et al (2003) Design, synthesis, and anticancer properties of 4,4′-dihydroxybenzophenone-2,4- dinitrophenylhydrazone and analogs. J Med Chem 46:4552-4563
12. Eilender DE, LoRusso P, Krementz ET et al (1998) Topical use of 4,4′-dihydroxy-benzophenone-2,4-dinitrophenylhydrazone (A-007) as a 0.25% gel in the treatment of malignant cutaneous metastases - a phase I study. In: Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, Amsterdam, NL 477 (abstr)
13. Eilender DE, McCormick C, Tornyos K (1999) Recurrent CD30/K1-1 - positive lymphoma of the skin treated with topical 4,4′-dihydroxybenzo-phenone-2, 4-dinitrophenylhydrazone (A-007) as a 0.25% gel. Proc Amer Soc Clin Onc 18:96 (abstr)
14. Rodgers AH, Subramanian S, Morgan LR (1995) High performance liquid chromatographic determination of 4,4′-dihydroxybenzophenone-2,4- dinitrophenylhydrazone (A-007) in plasma. J Chrom 670:365-368
15. Corbett TH, Lowichik N, Pugh S, Polin L, Panchapor C, White K, Knight J, Demchik L, Jones J, Jones L, Biernat L, LoRusso P, Foster B, Heibrun L, Rake J, Mattes KC, Perni R, Powles RG, Hiavac AG, Wentland MP, Coughlin SA, Baker L, Valeriote, F (1994) Antitumor activity of N-1-[[2-(dialkyamino) ethyl] amino]-9-oxo-9H-thioxanthen-4-yl-(methyl) methane sulfonamide (WYN 333777) and analogs. Exp Opin Investig Drugs 3(12):1281-1292
16. Thangaraj K, Morgan LR Benes E et al (1993) Aryl-2,4- dinitrophenylhudrazone anticancer activities in vitro against fresh human cancer cells. Breast Cancer Res Treat 21:21 (abstr)
17. Morgan LR, Rodgers AH, LeBlanc BW, Boue SM, Yang Y, Jursic BS, Cole RB (2001) Anticancer properties for 4,4′-dihydroxybenzophenone-2,4- dinitrophenylhydrazone (A-00)/3,7-diaminophenothiazine-5-ium double salts.Bioorg Med Chem Lett 11:2193-2195
18. Easmon J, Heinisch G, Purstinger G et al (2000) Synthesis and cytotoxic evaluation of analogs of the antiestrogenic agent 4,4′- dihydroxybenzophenone-2,4-dinitrophenylhydrazone. Proc Am Assoc Cancer Res 41:656 (abstr)